Company
Company
Accuray is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading-edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy.
Our Vision:
A future where the fear, pain and suffering of cancer are a thing of the past.
Our Mission:
To develop personalized, leading-edge treatment solutions that help cancer patients live longer, better lives.
Why - What We Do - is Important:
- To patients – Accuray offers new hope to cancer patients through innovations that help them live longer, better lives.
- To customers – Accuray’s leading-edge treatment solutions expand clinical opportunities for healthcare providers, helping them offer the best treatment for each patient.
- To investors – Accuray offers unique & well-differentiated products specifically designed for image-guided radiosurgery and IMRT; two rapidly growing market segments.
- To colleagues – Accuray colleagues are committed to fundamentally changing the future of cancer treatment and helping patients live longer, better lives.
Company Overview:
| Employees | More than 1,000 colleagues globally |
| Offices |
Sunnyvale, CA (Corporate Headquarters) Madison, WI Brussels, Belgium Paris, France Tokyo, Japan Hong Kong |
| Manufacturing |
Sunnyvale, CA Madison, WI Chengdu, Sichuan, China |
| Senior Management |
Euan S. Thomson, Ph.D. President & Chief Executive Officer Chris A. Raanes SVP, Chief Operating Officer Derek Bertocci SVP, Chief Financial Officer Kelly Londy, SVP, Chief Commercial Officer |
| Installed Base | 598 systems installed in 33 countries |
| Patient Treatments | More than 200,000 patients treated |
| Intellectual Property |
297 U.S. & Foreign patents issued 311 U.S. & Foreign patent applications pending |
Noteworthy Awards:
Accuray: Named a Technology Pioneer for 2008 by the World Economic Forum and ranked consistently in Deloitte’s "Technology Fast 500" fastest growing companies in North America since 2008
CyberKnife VSI System: Winner in the Best New Device category of the 2010 "Minnie Awards" given by AuntMinnie.com
CyberKnife System: Recipient of a "2010 Most Valuable Product" Award in the Radiation Therapy category given by RT Image
TomoTherapy System: Recipient of a "2009 Most Valuable Product" Award in the Radiation Therapy category given by RT Image
Our Technologies:
Accuray's CyberKnife and TomoTherapy Systems are highly complementary and both put the emphasis on patient-focused care. They serve distinct patient populations that are treated by the same medical specialty, radiation oncology. Accuray offerings include advanced, personalized technologies for the treatment of cancer and other diseases, ranging from high-precision radiosurgery for early-stage and localized disease to 3D image-guided, intensity modulated radiation therapy (IG-IMRT)for more advanced disease sites throughout the body.
![]() |
![]() |
|
CyberKnife® Robotic Radiosurgery System |
TomoTherapy® System |
| The first and only robotic radiosurgery system delivering customizable, non-surgical treatments for a broad range of tumors anywhere in the body. Only the CyberKnife® System allows practitioners to non-invasively deliver high doses of radiation to tumors with extreme accuracy and intense precision, providing personalized and tailored treatments that help clinicians pursue the best clinical outcomes for patients’ individual needs. | The TomoTherapy® System is a fully-integrated, 3D image-guided intensity modulated radiation therapy (IG-IMRT ) system. Through daily CT imaging, the TomoTherapy® System allows clinicians to give each patient the most accurate and highest quality individualized treatments specifically tailored to their needs. Unique helical delivery means a broader range of tumors can be treated, expanding options for more patients. |

